Terlipressin Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 0.85 mg/5 mL
Reference Brands: Terlivaz (USA)
Category:
Critical Care
Terlipressin is indicated in the treatment of bleeding oesophageal varices. The administration of terlipressin serves the emergency care for acute bleeding oesophageal varices until endoscopic therapy is available.
Terlipressin Injection is available in Injection
and strengths such as 0.85 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Terlipressin Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Terlipressin Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Terlipressin is a synthetic analogue of vasopressin and acts as a potent vasoactive agent used primarily in critical care and hospital settings. It works as a vasopressin receptor agonist, producing vasoconstriction that helps increase systemic vascular resistance and improve blood pressure. Terlipressin is especially valuable in patients where conventional vasopressors, such as norepinephrine, have shown limited effectiveness.
Clinically, terlipressin is approved for improving kidney function in adults with hepatorenal syndrome associated with rapid deterioration of renal function in patients with advanced liver disease. By selectively constricting splanchnic blood vessels, it improves renal perfusion and supports kidney recovery. Terlipressin is also widely used in the management of acute bleeding from esophageal varices, where it helps reduce portal hypertension and control hemorrhage.
Although terlipressin has been studied for use in norepinephrine-resistant septic shock, recent international guidelines advise against its routine use for septic shock in adults. Due to its strong vasoconstrictive properties, terlipressin should be administered intravenously under strict medical supervision, with careful monitoring to minimize potential cardiovascular and ischemic complications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing